R‑Zero, a biosafety company dedicated to developing the most effective hospital-grade technologies to reduce the spread of infectious disease, today announced $15M in new capital and remarkable business momentum, just three months after first introducing its germicidal UV device.
“In today’s world, nothing is more important than the health and safety of our families, fellow employees and frontline workers, but unfortunately the cost of effective disinfection protocols has been prohibitively expensive,” said Ira Ehrenpreis, Managing Partner at DBL Partners and R‑Zero board member. “Through innovation and cost reduction, R‑Zero democratizes access to safety for businesses and communities alike. In much the same way as companies in other critical industries have experienced exponential growth by unlocking new technologies and attracting a new breed of entrepreneurial talent, R‑Zero is similarly poised to benefit from impact investment dollars. The goal is to modernize the disinfection space with its breakthrough technology, aimed at addressing the critical societal issues around trust, appropriate health protocols, and the need for safer spaces.”
To learn more, please visit VentureBeat.com.